Gilead sets price of coronavirus drug remdesivir at $3,120 as Trump administration secures supply for 500,000 patients
Gilead Sciences, the maker of the first covid-19 treatment found to have worked in clinical trials, remdesivir, said Monday it will charge U.S. hospitals $3,120 for the typical patient with private insurance.
Soon after the announcement, the Trump administration said it had secured nearly all of the company’s supply of the drug for use in U.S. hospitals through September, with a contract for 500,000 treatment courses, which it will make available to hospitals at Gilead’s price.
Other developed countries will pay 25 percent less than the United States, a discount Gilead said reflects a need to make the drug as widely available as possible throughout the world.
The company has licensed generic manufacturers to produce the drug for developing countries, which will receive the treatment “at a substantially lower cost,” the company said.